EDIT - Editas Medicine

 Price: 63.50 (8/31/21)

Original entry: 49

OS: 68M

Float: 58M

Cash: $580M (about 40 months worth)

History: https://en.wikipedia.org/wiki/Editas_Medicine (including funding from Bill Gates)

Pipeline: https://www.editasmedicine.com/gene-editing-pipeline/

The run to 100 in December 2020 was on the back of EDIT filing for IND for EDIT-301 (focused on sickle cell disease)

It gave up all of that run, going all the way back to 30.

Things started ticking up again in June 2021 after sharing preclinical data on EDIT301 (June 11).  That took it to 60.  Then it dropped back down to 40 before it started the current run we’re on, which kicked off with the August 4th Business/Pipeline Update, which had several catalyst events in it - ir.editasmedicine.com/news-rel...

September 27 - Initial clinical data for EDIT-101 (Leber Congenital Amaurosis 10 (LCA10), adult cohort, low and mid-dose).  The mission here is to restore vision in adults and children. 

EOY - dosing on EDIT-301 ( sickle cell disease, currently in patient screening).  Preclinical data suggests this could be best in class treatment.

EOY - EDIT-301 IND filing - expanding indication to Beta-Thalassemia

As long as gene-editing stays in favor, this should be a good one long-term, it’s still undervalued in comparison to its peers.  EDIT has all-star talent on their team and are leveraging the latest CRISPR technology. https://www.editasmedicine.com/crispr-gene-editing/

They will likely just keep filing for more indications as they progress, which will only boost their value.

I picked this up originally at 49.  Sold at 54.  Didn’t realize what I had.  Then started scooping it up anytime it dipped below 60.  I’m now done trading (and buying) and holding for the 9/27 EDIT-101 data event.  I’ll be back for the end of the year IND and dosing, most likely.